Literature DB >> 23375312

Early allograft dysfunction is associated with excess resource utilization after liver transplantation.

K P Croome1, R Hernandez-Alejandro, N Chandok.   

Abstract

BACKGROUND: There are limited data on length of stay (LOS) following liver transplantation (LT), yet this is an important health services metric that directly correlates with early post-LT health care costs. The primary objective of this study was to examine the relationship between early allograft dysfunction (EAD) and LOS after LT. The secondary objective was to identify additional recipient, donor, and operative factors associated with LOS.
METHODS: Adult patients undergoing primary LT over a 32-month period were prospectively examined at a single center. Subjects fulfilling standard criteria for EAD were compared with those not meeting the definition. Variables associated with increased LOS on ordinal logistic regression were identified.
RESULTS: Subjects with EAD had longer mean hospital LOS than those without (42.5 ± 38.9 days vs 27.4 ± 31 days; P = .003). Subjects with EAD also had longer mean intensive care LOS (8.61 ± 10.28 days vs 5.45 ± 11.6 days; P = .048). Additional factors significantly associated with LOS included Model for End-Stage Liver Disease (MELD) score, recipient location before LT, and postoperative surgical complications.
CONCLUSIONS: EAD is associated with longer hospitalization after LT. MELD score, preoperative recipient location, and postoperative complications were significantly associated with LOS. From a cost-containment perspective, these findings have implications on resource allocation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23375312     DOI: 10.1016/j.transproceed.2012.07.147

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

1.  Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver-kidney transplant recipients.

Authors:  Masahiko Yazawa; Orsolya Cseprekal; Ryan A Helmick; Manish Talwar; Vasanthi Balaraman; Pradeep S B Podila; Sallyanne Fossey; Sanjaya K Satapathy; James D Eason; Miklos Z Molnar
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

2.  The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation.

Authors:  Tang Yunhua; Ju Weiqiang; Chen Maogen; Yang Sai; Zhang Zhiheng; Wang Dongping; Guo Zhiyong; He Xiaoshun
Journal:  J Clin Monit Comput       Date:  2017-08-22       Impact factor: 2.502

3.  Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model.

Authors:  Vatche G Agopian; Michael P Harlander-Locke; Daniela Markovic; Wethit Dumronggittigule; Victor Xia; Fady M Kaldas; Ali Zarrinpar; Hasan Yersiz; Douglas G Farmer; Jonathan R Hiatt; Ronald W Busuttil
Journal:  JAMA Surg       Date:  2018-05-01       Impact factor: 14.766

4.  Decreasing Significance of Early Allograft Dysfunction with Rising Use of Nonconventional Donors.

Authors:  Stephanie Ohara; Elizabeth Macdonough; Lena Egbert; Abigail Brooks; Blanca Lizaola-Mayo; Amit K Mathur; Bashar Aqel; Kunam S Reddy; Caroline C Jadlowiec
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

5.  Patterns and Outcomes Associated with Patient Migration for Liver Transplantation in the United States.

Authors:  Kristopher P Croome; David D Lee; Justin M Burns; Dana K Perry; Andrew P Keaveny; C Burcin Taner
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

6.  Time spent in hospital after liver transplantation: Effects of primary liver disease and comorbidity.

Authors:  Chutwichai Tovikkai; Susan C Charman; Raaj K Praseedom; Alexander E Gimson; Jan van der Meulen
Journal:  World J Transplant       Date:  2016-12-24

7.  Brain death-induced cytokine release is not associated with primary graft dysfunction: a cohort study.

Authors:  Tatiana Helena Rech; Geisiane Custódio; Leonardo Viliano Kroth; Sabrina Frighetto Henrich; Édison Moraes Rodrigues Filho; Daisy Crispim; Cristiane Bauermann Leitão
Journal:  Rev Bras Ter Intensiva       Date:  2019-03-21

8.  Prospective, single-centre, randomised controlled trial to evaluate the efficacy and safety of ischaemia-free liver transplantation (IFLT) in the treatment of end-stage liver disease.

Authors:  Changjun Huang; Shanzhou Huang; Yunhua Tang; Qiang Zhao; Dongping Wang; Weiqiang Ju; Lu Yang; Jian Zhang; Linwei Wu; Maogen Chen; Zhiheng Zhang; Zebin Zhu; Linhe Wang; Caihui Zhu; Yixi Zhang; Chengjun Sun; Wei Xiong; Yuekun Shen; Xiaoxiang Chen; Yi Ma; Anbin Hu; Xiaofeng Zhu; Jian Rong; Changjie Cai; Zhiyong Guo; Xiaoshun He
Journal:  BMJ Open       Date:  2020-05-05       Impact factor: 2.692

9.  A nomogram for prediction of early allograft dysfunction in living donor liver transplantation.

Authors:  Yu-Chen Ko; Hsin-I Tsai; Chao-Wei Lee; Jr-Rung Lin; Wei-Chen Lee; Huang-Ping Yu
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.